1. Home
  2. CRDF vs FDMT Comparison

CRDF vs FDMT Comparison

Compare CRDF & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDF
  • FDMT
  • Stock Information
  • Founded
  • CRDF 1999
  • FDMT 2013
  • Country
  • CRDF United States
  • FDMT United States
  • Employees
  • CRDF N/A
  • FDMT N/A
  • Industry
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • FDMT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRDF Health Care
  • FDMT Health Care
  • Exchange
  • CRDF Nasdaq
  • FDMT Nasdaq
  • Market Cap
  • CRDF 196.2M
  • FDMT N/A
  • IPO Year
  • CRDF N/A
  • FDMT 2020
  • Fundamental
  • Price
  • CRDF $2.63
  • FDMT $3.24
  • Analyst Decision
  • CRDF Strong Buy
  • FDMT Buy
  • Analyst Count
  • CRDF 4
  • FDMT 8
  • Target Price
  • CRDF $12.00
  • FDMT $30.29
  • AVG Volume (30 Days)
  • CRDF 1.1M
  • FDMT 505.1K
  • Earning Date
  • CRDF 05-20-2025
  • FDMT 05-20-2025
  • Dividend Yield
  • CRDF N/A
  • FDMT N/A
  • EPS Growth
  • CRDF N/A
  • FDMT N/A
  • EPS
  • CRDF N/A
  • FDMT N/A
  • Revenue
  • CRDF $683,000.00
  • FDMT $37,000.00
  • Revenue This Year
  • CRDF N/A
  • FDMT $13,270.27
  • Revenue Next Year
  • CRDF N/A
  • FDMT N/A
  • P/E Ratio
  • CRDF N/A
  • FDMT N/A
  • Revenue Growth
  • CRDF 39.96
  • FDMT N/A
  • 52 Week Low
  • CRDF $2.01
  • FDMT $2.24
  • 52 Week High
  • CRDF $5.64
  • FDMT $28.93
  • Technical
  • Relative Strength Index (RSI)
  • CRDF 41.22
  • FDMT 48.07
  • Support Level
  • CRDF $2.42
  • FDMT $3.19
  • Resistance Level
  • CRDF $2.87
  • FDMT $3.80
  • Average True Range (ATR)
  • CRDF 0.18
  • FDMT 0.28
  • MACD
  • CRDF 0.01
  • FDMT 0.03
  • Stochastic Oscillator
  • CRDF 24.42
  • FDMT 33.33

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: